THIS STORY HAS BEEN FORMATTED FOR EASY PRINTING

Therion to close, sell assets after cancer drug trial fails

By Stephen Heuser
Globe Staff / June 29, 2006

E-mail this article

Invalid E-mail address
Invalid E-mail address

Sending your article

Your article has been sent.

Text size +

Therion Biologics Corp. , a 15-year-old Cambridge company trying to develop a new breed of vaccines to fight cancer, will be shuttered and sold after its most promising drug candidate failed a pivotal human test, the company's chief executive said yesterday. (Full article: 635 words)

This article is available in our archives:

Globe Subscribers

FREE for subscribers

Subscribers to the Boston Globe get unlimited access to our archives.

Not a subscriber?

Non-Subscribers

Purchase an electronic copy of the full article. Learn More

  • $9.95 1 month archives pass
  • $24.95 3 months archives pass
  • $74.95 1 year archives pass